Sara van den Berg

76 Chapter 3 62. Frasca, D. and B.B. Blomberg, Aging, cytomegalovirus (CMV) and influenza vaccine responses. Human Vaccines and Immunotherapeutics, 2016. 12(3): p. 682-690. 63. Reed, R.G., R.N. Greenberg, and S.C. Segerstrom, Cytomegalovirus serostatus, inflammation, and antibody response to influenza vaccination in older adults: The moderating effect of beta blockade. Brain Behav Immun, 2017. 61: p. 14-20. 64. Merani, S., et al., Influenza vaccine-mediated protection in older adults: Impact of influenza infection, cytomegalovirus serostatus and vaccine dosage. Exp Gerontol, 2017. 65. van den Berg, S.P.H., et al., Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults. Front Immunol, 2018. 9: p. 82. 66. Belongia, E.A., et al., Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis, 2016. 16(8): p. 942-51. 67. Committee for Medicinal Products for Human Use (1997) Harmonisation of requirements for influenza vaccines . European Medicines Agency. https://www.ema.europa.eu/en/harmonisation- requirementsinfluenza-vaccines. Accessed 20 Dec 2018